In the present paper, we review the preclinical development of TG100-115, a PI3K (phosphoinositide 3-kinase) γ/δ isoform-specific inhibitor currently in clinical trials for the reduction of acute MI (myocardial infarction). An overview is presented outlining the pathogenesis of acute MI and the rationale for clinical use of PI3K γ/δ-specific inhibitors in this indication. TG100-115's broad anti-inflammatory activities are described, as well as its ability to discriminate between cellular signalling pathways downstream of receptor tyrosine kinase ligands such as vascular endothelial growth factor. Finally, we review TG100-115's potent cardioprotective activities as revealed in rigorous animal models of acute MI, and, based on these data, this compound's potential for clinical utility.
Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction
J. Doukas, W. Wrasidlo, G. Noronha, E. Dneprovskaia, J. Hood, R. Soll; Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction. Biochem Soc Trans 1 April 2007; 35 (2): 204–206. doi: https://doi.org/10.1042/BST0350204
Download citation file: